Testing for coronavirus disease 2019 (COVID-19) before procedures has become a fixture of City of Hope's efforts to protect patients with cancer and staff, noted Harlan Levine, MD, president of Strategy and Business Ventures at City of Hope.
Testing for coronavirus disease 2019 (COVID-19) before procedures and admissions has become a fixture of City of Hope's efforts to protect patients with cancer and our staff. Additionally, there are over 2 dozen projects focusing on aspects related to better controlling the pandemic, said Harlan Levine, MD, president of Strategy and Business Ventures at City of Hope.
Transcript
AJMC®: COVID-19 has changed ways of delivering care and conducting clinical trials. What strategies has City of Hope developed to deliver best-in-class care and foster innovation during the pandemic?
Dr Levine: Our philosophy is that cancer doesn't stop for COVID-19 and neither should we. As a NCI-Designated Cancer Center taking care of immunocompromised patients, we already excel at protecting patients against infections and preventing them from happening in the first place. But the COVID pandemic has led us to reevaluate all of our processes, and we've made changes to enhance our protection of our patients, but also our staff.
Initially, we did reduce our volumes, but at no point did we stop the necessary treatments or procedures or bone marrow transplants that people needed. Currently, to protect our patients and our staff, we’re testing for COVID-19 before most procedures and admissions. We also have drive-through testing for our out-patient clinics and for staff that come to the clinic.
Like all hospitals, we've had to modify our visitor policies during the COVID-19 pandemic. From a global point of view, our scientists have contributed to the global efforts to stem this horrible pandemic. We have over 2 dozen projects that either focus on vaccines, treatments, diagnostics, or other screening tools to help us better control the pandemic.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More